Bill Few Associates Inc. Increases Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Bill Few Associates Inc. boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 588 shares of the medical research company’s stock after purchasing an additional 35 shares during the period. Bill Few Associates Inc.’s holdings in Thermo Fisher Scientific were worth $238,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Hazlett Burt & Watson Inc. boosted its position in Thermo Fisher Scientific by 15.3% in the second quarter. Hazlett Burt & Watson Inc. now owns 1,760 shares of the medical research company’s stock worth $714,000 after purchasing an additional 233 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Thermo Fisher Scientific by 2.0% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 106,999 shares of the medical research company’s stock valued at $45,097,000 after buying an additional 2,062 shares in the last quarter. GW Henssler & Associates Ltd. lifted its position in shares of Thermo Fisher Scientific by 0.9% during the 2nd quarter. GW Henssler & Associates Ltd. now owns 37,057 shares of the medical research company’s stock valued at $15,025,000 after buying an additional 347 shares in the last quarter. Mitchell Sinkler & Starr PA lifted its position in shares of Thermo Fisher Scientific by 11.3% during the 2nd quarter. Mitchell Sinkler & Starr PA now owns 692 shares of the medical research company’s stock valued at $281,000 after buying an additional 70 shares in the last quarter. Finally, Criteria Caixa S.A.U. purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $6,171,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on TMO shares. Robert W. Baird lifted their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a research report on Thursday, July 24th. JPMorgan Chase & Co. lifted their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday. Hsbc Global Res cut Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Weiss Ratings reissued a “hold (c-)” rating on shares of Thermo Fisher Scientific in a research note on Saturday, September 27th. Finally, UBS Group lifted their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a research note on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $593.43.

Thermo Fisher Scientific Stock Down 1.8%

Shares of TMO opened at $524.95 on Monday. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The business’s 50 day moving average is $488.68 and its 200 day moving average is $447.49. The company has a market capitalization of $198.23 billion, a PE ratio of 30.36, a price-to-earnings-growth ratio of 2.85 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the previous year, the company posted $5.37 EPS. The company’s revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares of the company’s stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 400 shares of the business’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the transaction, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. This represents a 0.35% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock valued at $14,182,963 in the last quarter. 0.33% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.